Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

4 results

  • Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study

  • Magali Haas, Mariëlle Eerdekens, Stuart Kushner, Julia Singer, Ilse Augustyns, Jorge Quiroz, Gahan Pandina, Vivek Kusumakar
  • Journal:
    The British Journal of Psychiatry / Volume 194 / Issue 2 / February 2009
    Published online by Cambridge University Press:
    02 January 2018, pp. 158-164
    Print publication:
    February 2009
    • Article
      • You have access
    • PDF
    • HTML
    • Export citation
  • Background

    Effective treatments for adolescent schizophrenia are needed.

    Aims

    To compare efficacy and safety of two dosing regimens of risperidone.

    Method

    Double-blind, 8-week study. Patients, 13–17 years, with an acute episode of schizophrenia, randomised 1:1 to risperidone 1.5–6.0 mg/day (regimen A; n=125) or 0.15–0.6 mg/day (regimen B; n=132). Trial registration number: NCT00034749.

    Results

    Mean total Positive and Negative Syndrome Scale (PANSS) score improved significantly (P<0.001; effect size=0.49) from baseline to end-point for regimen A (mean=96.4 (s.d.=15.39) to mean=72.8 (s.d.=22.52)) compared with regimen B (mean=93.3 (s.d.=14.14) to mean=80.8 (s.d.=24.33)). Treatment-emergent adverse events occurred in 74% (regimen A) and 65% (regimen B) of patients; 4% of patients overall discontinued for adverse events. Mean change in body weight was 3.2 kg (s.d.=3.49) for regimen A and 1.7 kg (s.d.=3.29) for regimen B.

    Conclusions

    Adolescent patients in the regimen A group showed greater improvement in total PANSS compared with the regimen B group. Treatment was well tolerated.